Related Experiment Video

Updated: Apr 8, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination

N Gamal1, P Andreone2

  • 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Drugs of Today (Barcelona, Spain : 1998)
|June 23, 2015
PubMed

Insights

New interferon-free hepatitis C virus (HCV) treatments offer improved efficacy and tolerability. An all-oral regimen (ombitasvir/paritaprevir/ritonavir with dasabuvir) shows up to 100% sustained virologic response in genotype 1 HCV patients.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection affects 184 million globally, potentially leading to liver cirrhosis and failure.
  • Traditional PEGylated interferon/ribavirin therapy for HCV had limited efficacy and significant side effects.
  • Advances in antiviral therapy have introduced interferon-free regimens with better outcomes and tolerability.

Purpose of the Study:

  • To review current knowledge on a new all-oral interferon-free regimen for HCV.
  • To highlight the efficacy and safety of ombitasvir/paritaprevir/ritonavir co-packaged with dasabuvir.

Main Methods:

  • Review of scientific literature on novel HCV treatments.
  • Analysis of clinical data for the specified all-oral regimen.

Main Results:

  • The regimen ombitasvir/paritaprevir/ritonavir co-packaged with dasabuvir is FDA-approved for genotype 1 HCV.
  • This all-oral therapy demonstrates high sustained virologic response rates, up to 100%.
  • The treatment is reported to be safe and well-tolerated in patients, including those with compensated cirrhosis.

Conclusions:

  • Interferon-free regimens represent a significant advancement in HCV treatment.
  • The new all-oral combination therapy offers a highly effective and safe option for genotype 1 HCV patients.
  • Further research and clinical application of this regimen are warranted.

Keywords:
Chronic genotype 1Interferon-freeNS3/4A protease inhibitorNS5A inhibitorNS5B polymerase inhibitor

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.1K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.9K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
850
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
564